$GILD — what investors on X are saying

$GILDGilead Sciences, Inc. · Drug Manufacturers - General · $190B

$153.07

post+0.0%

Event thread

Key events, in time order

16 items

2026-10-15Company
Gilead strikes solid tumor drug deal with Vir
Multi-program collaboration to develop novel PRO-XTEN dual-masked therapies
D1 +2.5% · since -0.7%
2026-09-15 → 09-16CompanyBull
Gilead Expands PAHO Deal to 14 Latin American Countries
Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
D1 -0.1% · +5d +4.4%
2 waves of this story
- 2026-09-15 Expands access to twice-yearly lenacapavir for PrEP across Latin America and the Caribbean
- 2026-09-16 Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability

14 earlier events

2026-08-28 → 09-02ProductBull
Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval
Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
D1 -2.1% · +5d +3.7%
2 waves of this story
- 2026-08-28 FDA greenlights Bixlenvo for virologically suppressed adults with HIV, simplifying complex regimens
- 2026-09-02 Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
2026-09-01AnalystBull
Gilead Upgraded to Zacks Strong Buy
Zacks upgrades GILD to Strong Buy on earnings optimism, reflecting analyst positivity
D1 +2.4% · +5d -2.8%
2026-08-29Capital
GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts
Mixed institutional moves highlight divergent views on GILD
D1 +0.5% · +5d +0.2%
2026-08-28ProductBull
GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients
D1 -2.1% · +5d +3.7%
2026-08-26Company
GILD Executives to Present at Q3 2026 Investor Conferences
Company announcement confirms executives will speak at Wells Fargo Healthcare Conference on Sept 9
D1 -0.5% · +5d +1.0%
2026-08-06Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 -0.7% · +5d +5.6%
2026-08-05EarningsBear
Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance
Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
D1 -2.6% · +5d +3.1%
2 waves of this story
- 2026-08-05 Q2 revenue $7.8B beat, adj. EPS -$6.75, Veklury sales plunge, FY guidance lowered.
- 2026-08-05 Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
2026-08-048-K filing
8-K: Item 2.02, Item 9.01
D1 +3.1% · +5d +0.4%
2026-08-04Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 +3.1% · +5d +0.4%
2026-08-03Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 +0.7% · +5d +1.5%
2026-08-01CapitalBull
Multiple Institutions Initiate or Add Gilead Positions in Q1
Avidity bought 20k shares; Axiom initiated 4,858 shares, reflecting institutional moves
D1 +0.7% · +5d +1.5%
2026-07-21AnalystBear
Leerink Partners downgrades to Market Perform
D1 -2.2% · +5d +3.1%
2026-07-20CapitalBear
Multiple Institutions Trim Gilead Sciences Holdings in Q1
Boston Common, Dimensional, and Allspring disclosed reduced stakes in 13F filings, indicating institutional repositioning.
D1 -0.8% · +5d -2.0%
2026-07-06AnalystBull
HSBC upgrades to Buy
D1 -1.3% · +5d +1.4%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

16 items

2026-10-15Company
Gilead strikes solid tumor drug deal with Vir
Multi-program collaboration to develop novel PRO-XTEN dual-masked therapies
D1 +2.5% · since -0.7%
2026-09-15 → 09-16CompanyBull
Gilead Expands PAHO Deal to 14 Latin American Countries
Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
D1 -0.1% · +5d +4.4%
2 waves of this story
- 2026-09-15 Expands access to twice-yearly lenacapavir for PrEP across Latin America and the Caribbean
- 2026-09-16 Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
2026-08-28 → 09-02ProductBull
Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval
Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
D1 -2.1% · +5d +3.7%
2 waves of this story
- 2026-08-28 FDA greenlights Bixlenvo for virologically suppressed adults with HIV, simplifying complex regimens
- 2026-09-02 Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
2026-09-01AnalystBull
Gilead Upgraded to Zacks Strong Buy
Zacks upgrades GILD to Strong Buy on earnings optimism, reflecting analyst positivity
D1 +2.4% · +5d -2.8%
2026-08-29Capital
GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts
Mixed institutional moves highlight divergent views on GILD
D1 +0.5% · +5d +0.2%

11 earlier events

2026-08-28ProductBull
GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients
D1 -2.1% · +5d +3.7%
2026-08-26Company
GILD Executives to Present at Q3 2026 Investor Conferences
Company announcement confirms executives will speak at Wells Fargo Healthcare Conference on Sept 9
D1 -0.5% · +5d +1.0%
2026-08-06Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 -0.7% · +5d +5.6%
2026-08-05EarningsBear
Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance
Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
D1 -2.6% · +5d +3.1%
2 waves of this story
- 2026-08-05 Q2 revenue $7.8B beat, adj. EPS -$6.75, Veklury sales plunge, FY guidance lowered.
- 2026-08-05 Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
2026-08-048-K filing
8-K: Item 2.02, Item 9.01
D1 +3.1% · +5d +0.4%
2026-08-04Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 +3.1% · +5d +0.4%
2026-08-03Earnings
Earnings report
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
D1 +0.7% · +5d +1.5%
2026-08-01CapitalBull
Multiple Institutions Initiate or Add Gilead Positions in Q1
Avidity bought 20k shares; Axiom initiated 4,858 shares, reflecting institutional moves
D1 +0.7% · +5d +1.5%
2026-07-21AnalystBear
Leerink Partners downgrades to Market Perform
D1 -2.2% · +5d +3.1%
2026-07-20CapitalBear
Multiple Institutions Trim Gilead Sciences Holdings in Q1
Boston Common, Dimensional, and Allspring disclosed reduced stakes in 13F filings, indicating institutional repositioning.
D1 -0.8% · +5d -2.0%
2026-07-06AnalystBull
HSBC upgrades to Buy
D1 -1.3% · +5d +1.4%

$GILD (Gilead Sciences, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 16.4%)

Most active credible voices on $GILD

Recent headlines featuring $GILD

$GILD (Gilead Sciences, Inc.) — investor discussion on X

Five-factor rating: Sell (sector percentile 16.4%)

Most active credible voices on $GILD

Recent headlines featuring $GILD

Gilead strikes solid tumor drug deal with Vir

Gilead Expands PAHO Deal to 14 Latin American Countries

Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval

Gilead Upgraded to Zacks Strong Buy

GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts

GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients

GILD Executives to Present at Q3 2026 Investor Conferences

Earnings report

Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance

8-K: Item 2.02, Item 9.01

Earnings report

Earnings report

Multiple Institutions Initiate or Add Gilead Positions in Q1

Leerink Partners downgrades to Market Perform

Multiple Institutions Trim Gilead Sciences Holdings in Q1

HSBC upgrades to Buy

Bull vs bear

Discussion

Gilead strikes solid tumor drug deal with Vir

Gilead Expands PAHO Deal to 14 Latin American Countries

Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval

Gilead Upgraded to Zacks Strong Buy

GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts

GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients

GILD Executives to Present at Q3 2026 Investor Conferences

Earnings report

Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance

8-K: Item 2.02, Item 9.01

Earnings report

Earnings report

Multiple Institutions Initiate or Add Gilead Positions in Q1

Leerink Partners downgrades to Market Perform

Multiple Institutions Trim Gilead Sciences Holdings in Q1

HSBC upgrades to Buy